alexa Design And Clinical Evaluation Of A Novel Self-adjuvanting Peptide-based Pan Influenza A T-cell Vaccine
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

3rd International Conference on Vaccines & Vaccination
July 29-31, 2013 Embassy Suites Las Vegas, NV, USA

Campbell Bunce
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560.S1.016
Abstract
I mmune Targeting Systems (ITS) has developed a rationally designed, safe, self-adjuvanting vaccine technology that induces robust cell mediated immune (CMI) responses to peptide antigens. The vaccine concept is based on linking a fluorocarbon chain to long immunogenic peptides. These ?fluoropeptides? bearing specific physico-chemical properties spontaneously form micelles in solution and enhance immunogenicity by the formation of an in vivo short-term depot thereby allowing efficient exposure of peptide antigens to the immune system. ITS? has applied this Depovaccine? technology to its lead programme Flunisyn?, an influenza T cell vaccine designed to target all seasonal and pandemic strains of influenza A. Flunisyn consists of 6 fluoropeptides developed using a proprietary bioinformatics platform. Each fluoropeptide encapsulates multiple CD4+ and CD8+ T cell epitopes, derived from conserved internal influenza proteins, which are predicted to bind to multiple HLA-types thereby granting the vaccine broad population coverage irrespective of ethnicity. Flunisyn? has completed two dose finding studies in young, healthy adult volunteers and recently a third study in the elderly population (median age of 71 years). From the clinical studies, Flunisyn? was demonstrated to be safe and well tolerated across young and old members of the population, inducing a broad cross-reactive anti-viral CMI response to multiple, distinct influenza A viruses (H1N1 to H9N2). These properties offer the unique position for Flunisyn? as a truly pan-influenza A vaccine for seasonal and pandemic use. Flunisyn?s ability to induce a robust immune response in the elderly population is of particular importance where conventional, HA-based influenza vaccines have proven to be poorly effective.
Biography
Campbell Bunce has a Ph.D. in Immunology awarded by the School of Medicine, University of Manchester, UK. After a post-doctorate at Imperial College, London, he joined the biotechnology sector where he has been developing novel immunomodulating therapies and vaccines for 16 years. Campbell joined ITS as R&D Director in 2009 managing the company through the transition from pre-clinical research to clinical development of the platform Depovaccine technology. Campbell has published a number of papers on T cell immunology and novel immunomodulating technologies.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version